Most Frequent Side Effects from Clinical Trials
Lurbinectedin (brand name Zepzelca), approved for metastatic small cell lung cancer, commonly causes hematologic toxicities. In the pivotal PM14-128 trial (n=105), grade 3/4 events included neutropenia (57%), anemia (25%), and thrombocytopenia (17%). Non-hematologic effects hit fatigue (35%), nausea (30%), decreased appetite (25%), and dyspnea (20%). These occurred mostly within the first two cycles.[1][2]
How Side Effects Differ by Cancer Type
In advanced SCLC trials, myelosuppression dominates, but broader use in trials for mesothelioma or other solid tumors shows similar profiles with added risks like transaminitis (elevated liver enzymes, 20-30%). Real-world data from expanded access reports comparable rates, though severe events like febrile neutropenia arise in 5-10% of cases.[2][3]
Managing Common Toxicities in Practice
Neutropenia often requires G-CSF support; holds or dose reductions (to 2.6 mg/m2 or 2 mg/m2) cut severe events by 40%. Antiemetics control nausea effectively. Liver monitoring is key, as ALT/AST rises typically resolve post-infusion. Patients on prior platinum therapy face higher risks.[1][4]
What Patients Report Most Online and in Studies
Fatigue, nausea, and hair loss (15-20%) top patient forums and PRO data. Alopecia is non-scarring and reversible. Long-term users note cumulative bone marrow suppression, but median treatment duration is 4 cycles due to progression.[3][5]
Rare but Serious Risks to Watch
Febrile neutropenia (6%), pneumonia (5%), and hyperglycemia (4%) can be fatal. Transfusion needs hit 20% for anemia. Avoid in active infections; monitor CBC weekly first cycle.[1][2]
Sources
[1] FDA Zepzelca Label
[2] Trigo et al., Lancet Oncol 2020 (PM14-128 trial)
[3] Farago et al., Clin Cancer Res 2021
[4] NCT02454972 summary
[5] DrugPatentWatch.com - Zepzelca safety data